Literature DB >> 11830421

The lung in the antiphospholipid syndrome.

G Espinosa1, R Cervera, J Font, R A Asherson.   

Abstract

Patients with antiphospholipid syndrome (APS) may develop a broad spectrum of pulmonary disease. Pulmonary thromboembolism and pulmonary hypertension are the most common complications, but microvascular pulmonary thrombosis, pulmonary capillaritis, and alveolar haemorrhage have also been reported. Clinicians should seriously consider these types of vascular injury when evaluating patients with APS who present with dyspnoea, fever, and infiltrates on chest radiography.

Entities:  

Mesh:

Year:  2002        PMID: 11830421      PMCID: PMC1754043          DOI: 10.1136/ard.61.3.195

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  62 in total

1.  Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival. A case report.

Authors:  H Nagai; K Yasuma; T Katsuki; A Shimakura; K Usuda; Y Nakamura; S Takata; K Kobayashi
Journal:  Angiology       Date:  1997-02       Impact factor: 3.619

Review 2.  Chronic major-vessel thromboembolic pulmonary hypertension.

Authors:  K M Moser; W R Auger; P F Fedullo
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

3.  Operation for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients.

Authors:  M Ando; S Takamoto; Y Okita; R Matsukawa; N Nakanishi; S Kyotani; T Satoh
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

4.  Severe postpartum pulmonary, cardiac, and renal syndrome associated with antiphospholipid antibodies.

Authors:  M J Kupferminc; M J Lee; D Green; A M Peaceman
Journal:  Obstet Gynecol       Date:  1994-05       Impact factor: 7.661

5.  Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent.

Authors:  A Hussein; E Trowitzsch; M Brockmann
Journal:  Klin Padiatr       Date:  1999 Mar-Apr       Impact factor: 1.349

6.  Anticardiolipin antibodies are associated with pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus.

Authors:  M Miyata; K Suzuki; F Sakuma; H Watanabe; S Kaise; T Nishimaki; R Kasukawa
Journal:  Int Arch Allergy Immunol       Date:  1993       Impact factor: 2.749

7.  Adult respiratory distress syndrome associated with antiphospholipid antibody syndrome.

Authors:  S Ghosh; H D Walters; J H Joist; T G Osborn; T L Moore
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

8.  Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy.

Authors:  J Sandoval; M C Amigo; R Barragan; R Izaguirre; P A Reyes; M L Martinez-Guerra; A Palomar; A Gomez; R Garcia-Torres
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

9.  Antiphospholipid syndrome in a patient with rapidly progressive fibrosing alveolitis.

Authors:  A D Kelion; J R Cockcroft; J M Ritter
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

10.  Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases.

Authors:  J de la Mata; M A Gomez-Sanchez; M Aranzana; J J Gomez-Reino
Journal:  Arthritis Rheum       Date:  1994-10
View more
  24 in total

1.  [Decompensated heart failure as a result of a systemic disease].

Authors:  B Greiner; K Remde; H-M Lorenz; R Max
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-04-11       Impact factor: 0.840

Review 2.  [Systemic lupus erythematosus. A problem based approach].

Authors:  S Kleinert; M Feuchtenberger; H-P Tony
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

Review 3.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

4.  Antiphospholipid syndrome presenting as pulmonary thrombosis and pancreatitis in a young man.

Authors:  Sanat Phatak; Neelam Redkar; Meenakshi Amit Patil; Niteen D Karnik
Journal:  BMJ Case Rep       Date:  2012-12-12

5.  Nocardiosis in a patient with primary anti-phospholipid syndrome.

Authors:  Mehmet Soy; Müşerref Tatman Oktun; Nermin Tunçbilek; Nilay Ermantaş; Omür Okten; Gündeniz Altinay; Burhan Turgut
Journal:  Rheumatol Int       Date:  2006-01-10       Impact factor: 2.631

6.  The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.

Authors:  S Bucciarelli; G Espinosa; R A Asherson; R Cervera; G Claver; J A Gómez-Puerta; M Ramos-Casals; M Ingelmo
Journal:  Ann Rheum Dis       Date:  2005-05-26       Impact factor: 19.103

7.  A case of pulmonary tuberculosis presenting as diffuse alveolar haemorrhage: is there a role for anticardiolipin antibodies?

Authors:  Almerico Marruchella; Angela Corpolongo; Chiara Tommasi; Francesco N Lauria; Pasquale Narciso
Journal:  BMC Infect Dis       Date:  2010-02-20       Impact factor: 3.090

8.  Platelet thromboembolism after lung transplantation.

Authors:  Carles Bravo; Joaquim Majó; Fernando Ruiz; Laura Muntaner; Víctor Monforte; Joan Solé; José Maestre; Ferran Morell; Antonio Roman
Journal:  J Transplant       Date:  2009-05-25

9.  Efficacy of bosentan in the treatment of a patient with mixed connective tissue disease complicated by pulmonary arterial hypertension.

Authors:  Caterina Naclerio; Salvatore D'Angelo; Silvano Baldi; Gianluigi Tagliamonte; Salvatore Scarpato
Journal:  Clin Rheumatol       Date:  2009-08-04       Impact factor: 2.980

Review 10.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.